Aceclofenac, the active ingredient in Mervan, is an agent used for managing conditions characterized by chronic and acute pain driven by inflammation. The medication is explicitly considered relevant for easing pain and inflammation in chronic joint conditions.

What Mervan Treats: Main Uses and Benefits

Mervan is commonly applied across chronic musculoskeletal and joint disorders, primarily Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). It is also used to address acute conditions such as low back pain and localized inflammatory processes. The therapeutic focus is relevant for managing symptom clusters like persistent pain, joint tenderness, and physical stiffness.

“The medication is generally applied in situations where additional management of discomfort is required, especially when symptoms are driven by inflammatory states.”

The overall therapeutic benefit centers on supportive symptomatic management, helping to ease the overall symptom load and contributes to improved day-to-day comfort. In situations involving acute pain, Mervan is applied when symptoms intensify, providing short-term symptomatic assistance during phases where the patient experiences noticeable discomfort and functional strain.

Quick Fact: Relief for Pain and Inflammation
Primary Focus	Conditions involving persistent joint and tissue inflammation.
Benefit	Supports the management of chronic stiffness and discomfort.
Key Scenarios	Used in chronic arthritis and acute inflammatory flare-ups.

Official Population Eligibility for Mervan (Aceclofenac)

The use of Mervan is formally restricted by regulatory authorities based on a patient's age, physiological status, and coexisting health conditions. The official profile defines clear boundaries for who may use the medicine.

Category	Official Regulatory Status
Approved Age Group	Adults (18 years and older)
Absolute Contraindication	Severe Heart Failure (NYHA II-IV); Severe Hepatic or Renal Failure; Active GI Bleeding/Ulcers; Third Trimester of Pregnancy; Hypersensitivity to NSAIDs.
Not Recommended	Children/Adolescents (under 18); Women attempting to conceive; Breastfeeding mothers.

Condition-Specific Eligibility Rules

• Patients with mild to moderate hepatic or renal impairment require close medical surveillance.
• The medicine is contraindicated in individuals with a history of recurrent gastrointestinal hemorrhage or peptic ulceration.
• Use requires careful consideration and monitoring in the elderly, who have an increased risk of severe adverse reactions.
• Patients with established cardiovascular conditions, such as ischemic heart disease, are typically prohibited from use.

Connection to the overall eligibility profile: Regulatory documents establish the official eligibility profile by first defining absolute prohibitions, such as severe organ failure and active GI bleeding, as formal contraindications. The profile limits use by designating the medicine as not recommended for the pediatric population and breastfeeding mothers due to insufficient safety data or known risks, thereby reserving the medicine for authorized use in adults under specific monitored conditions.

Interactions with other medicines and products

Interaction scope

Property	Value
Medicinal product categories with documented interactions	Other NSAIDs (including COX-2 inhibitors), Anticoagulants, Antiplatelet Agents, SSRIs, Corticosteroids, Diuretics, Anti-hypertensives (ACE-inhibitors, ARBs), Oral Antidiabetic Agents, Nephrotoxic Agents.
Specific interacting medicines	Lithium, Digoxin, Methotrexate, Mifepristone, Warfarin, Zidovudine.
Mechanistic basis of interactions	Pharmacodynamic: Increased risk of bleeding (additive effect with antiplatelet/anticoagulant drugs), antagonism (reduced effect of anti-hypertensives/diuretics). Pharmacokinetic: Inhibition of renal clearance, resulting in increased plasma concentrations of co-administered drugs.
Timing-based interaction rules	Must not be used for 8–12 days after Mifepristone administration to prevent the reduction of Mifepristone's effect.
Population-specific interaction notes	Risk of acute renal insufficiency is increased when co-administered with ACE-inhibitors or ARBs in elderly patients or those with compromised renal function.
Interaction-related restrictions	Avoid concomitant use with other NSAIDs, including COX-2 selective inhibitors and high-dose aspirin.

Interaction classifications (high-level)

Classification	Value
Interaction severity classification	Contraindicated (combination with other NSAIDs); Requires caution/close monitoring/dosage adjustment (Lithium, Methotrexate, Anticoagulants).
Regulatory basis	Summarized data based on international Summary of Product Characteristics (SmPC) documents and FDA Prescribing Information.
Interaction-context constraints	Co-administration with potassium-sparing diuretics may require monitoring of serum potassium; co-administration with anti-hypertensives may require monitoring of renal function.

Resulting interaction structure

Official regulatory documents classify Mervan's interaction profile around two main risks: the pharmacodynamic risk of additive toxicity, which includes increased risk of bleeding with anticoagulants and SSRIs; and the pharmacokinetic risk of altered clearance for drugs like Lithium and Methotrexate, leading to elevated plasma exposure. The profile establishes formal restrictions, such as the avoidance of other NSAIDs, and a specific timing constraint after Mifepristone administration. These constraints define combinations that are formally prohibited or require specific management as stated in the prescribing information.

Modulation of Inflammatory Signal Production

The core mechanism involves the inhibition of the Cyclooxygenase (COX) enzyme system, specifically targeting the COX-2 isoform. This molecular blockade interrupts the Arachidonic Acid Cascade, which reduces the synthesis of signaling molecules called Prostaglandins ( PGE2). This reduction in PGE2 concentration modulates the chemical processes linked to increased vascular permeability and vasodilation in local tissues.

Attenuation of Peripheral Nociceptor Sensitivity

The resulting reduction in Prostaglandin levels affects the nervous system, as Prostaglandins are key chemical sensitizers for peripheral nociceptors (sensory nerve endings). The drug's mechanism elevates the activation threshold of these sensory neurons, modulating their responsiveness to mechanical and chemical stimuli within the nociceptive signaling pathway.

Mechanism Augmentation by Active Metabolite

The mechanism is augmented by metabolic conversion, where the original compound is transformed into the active substance, Diclofenac. This metabolite also acts as a COX inhibitor, providing a complementary molecular action that contributes to the overall suppression of the inflammatory mediator pathway.

How Mervan is Used: Administration Guidelines

This section describes the administration and dosing guidelines for Aceclofenac (Mervan) as stipulated in prescribing information.

Administration Scope

Category	Usage Guideline
Route of Administration	The medicine is administered via the oral route (tablets) or as a topical cream/gel (cutaneous use).
Standard Dosing Schedule	The standard oral regimen is 100 mg per dose, taken twice daily. The maximum daily intake is 200 mg.
Timing in Relation to Meals	Oral tablets should be swallowed whole, preferably with or after food. This instruction is included to manage tolerance.
Preparation Requirements	Sustained-release (SR) forms, which may be dosed as 200 mg once daily, must not be crushed or chewed to maintain the intended release profile.
Population Adjustments	For patients with mild to moderate hepatic impairment, the initial daily dose is suggested to be reduced to 100 mg (once daily).
Missed Dose Rule	If a dose is missed, patient information specifies to take it as soon as remembered, unless the next scheduled dose is imminent, in which case the missed dose is skipped; a double dose must not be taken.

Resulting Procedural Structure

The use protocol establishes a systemic dosing regimen of 100 mg administered twice daily, defining the foundational schedule for oral treatment. The need to reduce the dose to 100 mg once daily for specific hepatic impairment confirms a modification for certain populations. Furthermore, labeling dictates that extended-release formulations must be swallowed whole to preserve the drug's action over time, ensuring proper administration as designed by the formulation.

Research evidence / Overview of studies for Mervan

Evidence for Use in Chronic Joint Conditions (Osteoarthritis and Rheumatoid Arthritis)

Research exploring the active ingredient in Mervan, Aceclofenac, in Osteoarthritis (OA) has included many short-to-intermediate term randomized controlled trials (RCTs) and subsequent systematic reviews. These studies monitored outcomes related to physical discomfort, such as pain intensity scores, and outcomes reflecting daily functioning, specifically using scales like the WOMAC Index to assess joint mobility and stiffness.

Studies reported measurements related to pain intensity and measured changes in functional scores during the study period. Findings described patterns observed in the studies that used other active comparator medications. However, certainty remains low regarding whether the studies explored effects on the underlying structural changes associated with OA. Existing research provides limited insight into the maintenance of symptomatic patterns over very long periods.

Similar research has explored Aceclofenac in Rheumatoid Arthritis (RA), with studies tracking outcomes capturing phases of heightened symptom activity, such as the duration of morning stiffness, joint swelling counts, and joint tenderness scores. Research described measured changes during the study period for these symptomatic markers. The evidence base primarily describes short-term symptomatic patterns and does not characterize potential effects on long-term disease progression.

Evidence for Use in Inflammatory Spinal Conditions (Ankylosing Spondylitis)

The active ingredient in Mervan was evaluated in studies for Ankylosing Spondylitis (AS). Studies explored outcomes linked to inflammatory or irritative states, focusing on measures of pain, stiffness, and assessment using functional capacity indices like the BASDAI. Studies reported measurements related to symptomatic patterns observed in the trials. However, the available evidence remains largely centered on short-term symptom control.

What is Still Uncertain About the Research Record for Mervan

The body of evidence, while providing context, still presents several areas of uncertainty. Follow-up durations were limited across many studies, particularly in the context of chronic conditions like OA. This means there is limited information for long-term outcomes and the potential for durable changes over years. Additionally, evidence quality varies across studies, and some systematic reviews have noted high variation among the trials. Data for specific groups, such as children and pregnant populations, have limited representation in the clinical research record.

Key Studies & References

1. A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders
2. Efficacy and safety of aceclofenac-cr and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study

Common questions about Mervan (FAQ)

---

Q: Is Mervan the same type of medicine as ibuprofen or naproxen?

A: Yes. Mervan, which contains the active ingredient Aceclofenac, is officially classified as a Non-Steroidal Anti-Inflammatory Drug, or NSAID. This means it belongs to the same core drug class as both ibuprofen and naproxen, which are also NSAIDs.

---

Q: How quickly should I expect Mervan to start relieving pain?

A: Official pharmacological data indicates that Aceclofenac is absorbed quickly after being taken by mouth. Generally, the highest concentrations in the bloodstream are reached approximately one to three hours after taking a tablet.

---

Q: How long does the effect of one Mervan tablet typically last?

A: The half-life of Mervan is about 4 to 4.3 hours, which is the time it takes for half of the substance to be eliminated from the body. Since the standard formulation follows a twice-daily dosing regimen, the effect is anticipated to cover a 12-hour interval.

---

Q: What is the difference between Mervan and Mervan SR?

A: Mervan SR refers to a Sustained-Release formulation. This type of tablet is specifically designed to release the medicine slowly and consistently over a longer period. Because of this formulation difference, Mervan SR is usually dosed once daily, compared to the standard Mervan tablet, which typically follows a twice-daily administration schedule.

---

Q: Is feeling dizzy a common side effect of taking Mervan?

A: Yes, regulatory documents list dizziness as a common side effect associated with the use of Mervan. This possibility is noted in the product information.

---

Q: Does Mervan interact with common over-the-counter cold or flu medicines?

A: The official prescribing information cautions against taking Mervan with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are often ingredients in cold or flu remedies. Combining these types of medicines may lead to an increased risk of side effects.

---

Q: Is Mervan safe for people who have kidney problems?

A: Severe kidney failure is a formal contraindication. For those with mild to moderate kidney impairment, the medicine should be used with caution. Official guidance states that regular monitoring of kidney function is advised.

---

Q: Is Mervan ever prescribed to teenagers or children?

A: The medicine is generally not recommended for use in children and adolescents under 18 years of age. This is because official data on its safety and effectiveness in this specific age group has not been fully established.

---

Q: Is it normal to feel a bit tired or drowsy when first starting Mervan?

A: Yes, official safety documents list both drowsiness and fatigue as possible undesirable effects of taking Aceclofenac.

---

Q: Can Mervan be taken during pregnancy or while breastfeeding?

A: Mervan is contraindicated during the third trimester of pregnancy due to established safety concerns. For the first and second trimesters, it should be avoided unless a healthcare provider determines it is absolutely necessary. Use is also generally not recommended while breastfeeding.

---

Q: Can Mervan be crushed or split, or must it be swallowed whole?

A: The standard Mervan tablet is intended to be swallowed whole. Regulatory instructions specify that the tablet should not be broken, chewed, or crushed before consumption.

---

Q: Should Mervan be taken with food, or can it be taken on an empty stomach?

A: Official administration instructions state that Mervan tablets should preferably be taken with or after food. This instruction is provided to help minimize any stomach irritation or discomfort.

---

Q: What should I do if I accidentally take two doses of Mervan too close together?

A: If a suspected overdose occurs, possible symptoms include headache, nausea, and stomach irritation. In such cases, it is necessary to seek emergency medical attention, as supportive symptomatic treatment may be required.

---

Q: Is Mervan known to cause water retention or swelling in the ankles?

A: Yes, water retention, also known as oedema (swelling), is listed in regulatory documents as a very rare side effect associated with the use of Aceclofenac.

---

Q: Does Mervan make you sensitive to the sun?

A: While severe sun sensitivity is rare, skin reactions like rash and dermatitis are listed as uncommon side effects. The potential for sun-related skin reactions is noted in the broader context of NSAID use.

---

Q: Can Mervan affect my mood or cause headaches?

A: Yes, headache is a listed possible side effect. Depression is also noted in regulatory information as a very rare psychiatric undesirable effect.

---

Q: Why is Mervan sometimes prescribed for toothache or dental pain?

A: Mervan's primary function is to relieve pain and inflammation. While its main indications are for joint and muscle conditions, its potent anti-inflammatory properties mean it can be used to manage acute inflammatory pain, such as that caused by dental issues.

---

Q: Is there a maximum time frame for how long Mervan should be used continuously?

A: Clinical studies often examine Mervan for periods of several months. Regulatory guidance emphasizes that long-term use requires periodic monitoring of kidney and liver function. Official guidance indicates that treatment should be regularly reviewed.

---

Q: How common is an increase in liver enzyme levels while on Mervan?

A: According to official regulatory summaries, an increase in liver enzyme levels is a common side effect of Aceclofenac. When persistently elevated enzyme levels occur, official documents state that consideration should be given to withdrawing the drug.

---

Q: Is there a link between Mervan use and increased risk of bleeding?

A: Yes. Regulatory warnings state that Mervan can prolong the time it takes for blood to clot and may increase the risk of bleeding in the stomach or intestines. This risk can exist throughout the course of treatment.

---

Q: Can someone with a stomach ulcer history take Mervan under supervision?

A: A history of recurrent stomach ulcers or bleeding is an absolute contraindication for Mervan. For individuals with only a suggestive history of ulceration, close medical monitoring is indicated, and the initiation of treatment typically requires the lowest effective dose.

---

Q: Can I drive or operate machinery while taking Mervan?

A: Since side effects like dizziness, drowsiness, and visual disturbances are possible, individuals should not drive or operate machinery if they experience these effects. This warning is included in the official product information.

---

Q: Does Mervan change how diuretics (water pills) work in the body?

A: Yes, regulatory information on drug interactions confirms that Mervan may inhibit the activity of diuretics, which are commonly known as water pills. This could potentially reduce their overall effectiveness.

---

Q: What are the ingredients in Mervan besides the active drug?

A: Besides the active drug, Aceclofenac, Mervan tablets contain various inactive ingredients called excipients. These can include substances like Microcrystalline Cellulose, along with other components used for the tablet body, coating, and color.

---

Q: Can Mervan be used for menstrual pain relief?

A: Mervan is primarily indicated for joint and muscle conditions. However, some regulatory mentions include its use for conditions like primary dysmenorrhea (menstrual pain), due to its properties as an anti-inflammatory pain reliever.

---

Q: Is Mervan used for types of back pain other than lumbago?

A: Yes. The medicine is generally indicated for the relief of pain and inflammation associated with a range of joint and muscle conditions, which encompasses many different forms of acute and chronic back pain.

---

Q: Are there any clinical trials that compare Mervan to other NSAIDs?

A: The regulatory summaries of Mervan's clinical effectiveness mention that studies have been performed using 'other active comparator medications.' This indicates that its efficacy in conditions like osteoarthritis and rheumatoid arthritis has been assessed in comparison with other treatments.

Storage and Disposal Requirements

The storage of Mervan (Aceclofenac) must align strictly with the environmental and handling requirements documented in official regulatory labeling to ensure product stability and safety.

Requirement	Official Regulatory Statement
Storage Temperature	Store at a temperature not exceeding 30 C or below 25 C, depending on the regional label.
Environmental Protection	The product must be protected from light and kept away from moisture in a dry place.
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal	Dispose of any unused product or waste material in accordance with local requirements.

Regulatory instructions advise against disposing of the medicine via wastewater or general household trash. Storage conditions are essential for maintaining the product's documented shelf life.